Skip to content
MarketScale
‹ Back to Industries

Sciences

Overcoming Problems with Hybrid Rocket Engines is Key to Launching Us Further into Space

Hybrid rocket engines combine elements of both liquid and solid propulsion systems to offer improved efficiency, safety, and control compared to traditional rocket technologies. Advances in hybrid propulsion are seen as a key enabler for more accessible and cost-effective space exploration. Greater accessibility to space could accelerate scientific discovery and technological innovation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · HybridRobert FabianRocket EnginesSpace
Share

Key takeaways

01

Hybrid rocket engines offer a middle ground between liquid and solid propulsion, providing better control and safety.

02

Improved rocket technology lowers barriers to space exploration for commercial and scientific missions.

03

Ongoing development of hybrid engines could unlock new opportunities for deep space travel and research.

Hybrid isn’t just the word with us earthlings, it’s also the next big thing in space technology. Hybrid rocket engines have been developed to increase efficiency and control over more established liquid and solid rocket engines. With better rocket technology comes more accessible space exploration, meaning the potential for scientific discoveries and technological advancements grows exponentially. In fact, according to a report by Morgan Stanley, the global space industry could be worth $1.1 trillion or more by 2040.

Still, while hybrid rockets offer certain advantages over the more traditional rockets, they also come with several drawbacks, including the fact that refueling hybrid rockets is more challenging than refueling liquid and solid rockets. Large hybrid orbital rockets also require turbopumps, but turbopumps can’t use the same fuel and oxidizer as in liquid-propellant rockets. Finally, there hasn’t been as much research on hybrid rockets as with other rockets, so many of their problems have not been fully addressed.

Private aerospace company Vaya Space has been making waves in the industry with its revolutionary Vortex hybrid engine technology. Robert Fabian, the company’s Chief Operating Officer, offers deeper insights into this new technology and its potential impact on space travel.

Robert’s Thoughts:

“What makes Vaya Space unique really is our engine technology, what we call the Vortex hybrid engine. We’ve taken the historical problems of hybrid engines and core performance and combustion instability and solved them, producing an engine that’s significantly cheaper, significantly simpler, and significantly safer than anything else out there on the market.

When I first heard about this technology, I didn’t believe it. I had to do the math myself to make sure it would work, and I’ve watched it go from math on a page and a concept to lab scale tests, to larger engine tests, to flight tests, and I’m really looking forward to seeing the production engine for our Dauntless launch vehicle fire for the first time.”

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences